Ireland’s government has defended its approach to rare disease treatment access while outlining a series of reforms intended to accelerate reimbursement decisions and improve availability of specialist medicines.

Speaking during parliamentary discussions on healthcare priorities, Health Minister Jennifer Carroll MacNeill said the current system is being strengthened through policy reform, pricing agreements and expanded support mechanisms aimed at improving outcomes for patients living with rare conditions.

Rare diseases affect an estimated 300,000 people in Ireland, with many patients experiencing long diagnostic pathways and extended waits before treatment becomes available. Government measures are increasingly focused on reducing barriers across diagnosis, evaluation and access to therapies.

Central to these efforts is the National Rare Disease Strategy 2025–2030, which establishes a framework to improve diagnosis, treatment pathways and long-term support. Authorities are also progressing implementation plans designed to strengthen data collection and expand newborn screening programmes.

Alongside broader healthcare reforms, Ireland is targeting improvements to medicines reimbursement processes. New pricing arrangements introduced earlier this year are intended to support a phased move toward a 180-day reimbursement timeline by early 2029.

The government has also initiated an end-to-end review of medicines approval and reimbursement systems and is piloting an early access approach for rare disease treatments.

However, debate continues around whether current mechanisms move quickly enough to meet patient needs. Opposition representatives argued that reimbursement models used for standard medicines may not fully reflect the complexity of evaluating therapies for smaller patient populations.

Several cases raised during discussions highlighted concerns about prolonged access timelines for certain rare disease medicines already authorised at European level.

For pharmaceutical companies and market access teams, the developments signal continued momentum toward reimbursement reform, with growing emphasis on faster evaluation pathways, stronger collaboration and earlier engagement to support patient access.

Read more about Ireland’s rare disease medicines strategy and reimbursement developments in the original report.